Showing results (581-590 of 2,688) with videos related to

Sort By:
Pageof 269
The Lancet. Infectious Diseases|November 9, 2024
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 studyPrasad S Kulkarni, Anand Kawade, Sunil Kohli, et al.
The Lancet. Infectious Diseases|August 10, 2024
Ebola virus disease mathematical models and epidemiological parameters: a systematic reviewRebecca K Nash, Sangeeta Bhatia, Christian Morgenstern, et al.
The Lancet. Infectious Diseases|August 12, 2024
The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and preventionMarion P G Koopmans, Casey Barton Behravesh, Andrew A Cunningham, et al.
The Lancet. Infectious Diseases|August 12, 2024
Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016-22: an interrupted time-series analysis and modelling studyLuc E Coffeng, Sake J de Vlas, Rudra Pratap Singh, et al.
The Lancet. Infectious Diseases|July 11, 2024
Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature reviewKasra Shirini, Shani Kamberi, Cynthia Drachenberg, et al.
The Lancet. Infectious Diseases|August 4, 2024
Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trialAhmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsHalimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
The Lancet. Infectious Diseases|August 15, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b studyRobert McMahon, Sebastian Toepfer, Natascha Sattler, et al.
The Lancet. Infectious Diseases|July 6, 2024
The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation-a consensus statementElse M Bijker, Lyn Horn, Sylvia LaCourse, et al.
The Lancet. Infectious Diseases|July 4, 2024
Lassa fever research priorities: towards effective medical countermeasures by the end of the decadeKristine A Moore, Julia T Ostrowsky, Angela J Mehr, et al.
Pageof 269